Kim Chulmin, Park Kui Young, Ahn Seohee, Kim Dong Ha, Li Kapsok, Kim Do Won, Kim Moon-Beom, Jo Sun-Jin, Yim Hyeon Woo, Seo Seong Jun
Department of Family Medicine, School of Medicine, The Catholic University of Korea, Seoul, Korea.
Department of Dermatology, Chung-Ang University College of Medicine, Seoul, Korea.
Ann Dermatol. 2015 Jun;27(3):298-305. doi: 10.5021/ad.2015.27.3.298. Epub 2015 May 29.
Atopic dermatitis is a global public health concern owing to its increasing prevalence and socioeconomic burden. However, few studies have assessed the economic impact of atopic dermatitis in Korea.
We conducted a cost analysis of atopic dermatitis and evaluated its economic impacts on individual annual disease burden, quality of life, and changes in medical expenses with respect to changes in health related-quality of life.
The cost analysis of atopic dermatitis was performed by reviewing the home accounting records of 32 patients. The economic impact of the disease was evaluated by analyzing questionnaires. To handle uncertainties, we compared the results with the data released by the Health Insurance Review & Assessment Board on medical costs claimed by healthcare facilities.
The direct cost of atopic dermatitis per patient during the 3-month study period was 541,280 Korean won (KRW), and expenditures on other atopic dermatitis-related products were 120,313 KRW. The extrapolated annual direct cost (including expenditures on other atopic dermatitis-related products) per patient was 2,646,372 KRW. The estimated annual indirect cost was 1,507,068 KRW. Thus, the annual cost of illness of atopic dermatitis (i.e., direct+indirect costs) was estimated to be 4,153,440 KRW.
The annual total social cost of atopic dermatitis on a national level is estimated to be 5.8 trillion KRW.
由于特应性皮炎患病率不断上升及其社会经济负担，它已成为一个全球公共卫生问题。然而，很少有研究评估其在韩国的经济影响。
我们对特应性皮炎进行了成本分析，并评估了其对个人年度疾病负担、生活质量以及与健康相关生活质量变化相关的医疗费用变化的经济影响。
通过查阅32例患者的家庭账目记录进行特应性皮炎的成本分析。通过分析问卷调查评估该疾病的经济影响。为处理不确定性，我们将结果与健康保险审查与评估委员会公布的医疗机构申报医疗费用数据进行了比较。
在3个月的研究期间，每位患者特应性皮炎的直接成本为541,280韩元，其他与特应性皮炎相关产品的支出为120,313韩元。每位患者推算的年度直接成本（包括其他与特应性皮炎相关产品的支出）为2,646,372韩元。估计年度间接成本为1,507,068韩元。因此，特应性皮炎的年度疾病成本（即直接成本 + 间接成本）估计为4,153,440韩元。
全国范围内特应性皮炎的年度社会总成本估计为5.8万亿韩元。
